Market Overview

UPDATE: Piper Jaffray Raises PT to $102 on CR Bard on Higher Large-Cap Multiples

Share:
Related BCR
Earnings Recap For January 28
Earnings Scheduled For January 28, 2016
MedTech Series: Why Medical Technology Companies Should Have A Place In Your Portfolio (Seeking Alpha)

Piper Jaffray reiterates its Neutral rating on CR Bard (NYSE: BCR) and increases its price target on shares from $92 to $102.

Piper Jaffray notes, "We are raising our price target from $92 to $102/share to incorporate as our new higher median 2012 multiple for large caps (we use 2012 median multiples applied to our 2013 estimates) shifted from 13.0x to 13.6x. We are keeping our FY13 estimate constant at $7.10 EPS. We are also adding $5.40/share to account for a discounted, fully taxed cash benefit from a recent patent infringement ruling (in escrow). We remain Neutral on shares."

BCR closed at $107.83 on Monday.

Latest Ratings for BCR

DateFirmActionFromTo
Jan 2016JMP SecuritiesMaintainsMarket Outperform
Nov 2015CitigroupInitiates Coverage onBuy
Sep 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (BCR)

Get Benzinga's Newsletters